These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 10672554)
1. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease]. Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554 [TBL] [Abstract][Full Text] [Related]
2. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report]. Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435 [TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis]. Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433 [TBL] [Abstract][Full Text] [Related]
4. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer. Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680 [TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of the determination of oxidation and acetylation phenotype in patients with multiple sclerosis]. Milejski P; Orzechowska-Juzwenko K; Pawlik J; Kamienowski J; Horoch E; Niewiński P; Hurkacz M Neurol Neurochir Pol; 1996; 30(4):571-9. PubMed ID: 9045059 [TBL] [Abstract][Full Text] [Related]
6. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease]. Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787 [TBL] [Abstract][Full Text] [Related]
7. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Clark DW Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977 [TBL] [Abstract][Full Text] [Related]
8. [Oxidation phenotype as a risk factor for development of allergic diseases]. Niewiński P; Orzechowska-Juzwenko K; Patkowski J; Wolańczyk-Medrala A; Nittner-Marszalska M; Rzemisławska Z Pol Arch Med Wewn; 1999 Jan; 101(1):23-7. PubMed ID: 10592724 [TBL] [Abstract][Full Text] [Related]
9. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Christensen PM; Gøtzsche PC; Brøsen K Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130 [TBL] [Abstract][Full Text] [Related]
10. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer]. Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818 [TBL] [Abstract][Full Text] [Related]
11. [Occurrence of the fast acetylation phenotype in persons with the radicular syndrome. Preliminary report]. Milejski P; Orzechowska-Juzwenko K; Tota B; Krzysztoń Z Neurol Neurochir Pol; 1987; 21(6):511-5. PubMed ID: 3449771 [TBL] [Abstract][Full Text] [Related]
12. N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population. Bialecka M; Gawronska-Szklarz B; Drozdzik M; Honczarenko K; Stankiewicz J Eur J Clin Pharmacol; 2002 Feb; 57(12):857-62. PubMed ID: 11936704 [TBL] [Abstract][Full Text] [Related]
13. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720 [TBL] [Abstract][Full Text] [Related]